Valuation: Serina Therapeutics, Inc.

Market Cap 31.94M 27.92M 25.76M 23.74M 44.75M 3.08B 45.75M 308M 121M 1.51B 120M 117M 5.19B P/E 2026 *
-1.09x
P/E 2027 * -1.36x
Enterprise Value 31.94M 27.92M 25.76M 23.74M 44.75M 3.08B 45.75M 308M 121M 1.51B 120M 117M 5.19B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
14.04%
Yield 2026 *
-
Yield 2027 * -
1 day+7.58%
1 week-0.47%
Current month+9.79%
1 month+1.43%
3 months+3.90%
6 months-31.29%
Current year+11.34%
1 week 1.93
Extreme 1.9301
2.2
1 month 1.71
Extreme 1.7101
2.28
Current year 1.22
Extreme 1.22
4.08
1 year 1.22
Extreme 1.22
7.92
3 years 1.22
Extreme 1.22
19.93
5 years 1.22
Extreme 1.22
19.93
10 years 1.22
Extreme 1.22
19.93
Date Insider Type Main position Quantity % Market Cap.
07/07/26 Buy

Director

1,000 0.0067%
17/06/26 Free

Director

15,250 0.1017%
17/06/26 Other

Director

15,250 0.1017%
Change 5-day change 1-year change 3-year change Capi.($)
+7.58%-0.47%-60.26% - 31.94M
+0.24%-1.54%+52.85%+71.85% 53.83B
-7.17%-4.39%+42.72%+73.32% 52.1B
+0.80%-6.31%+5.62%+417.78% 23.48B
-0.09%-0.01%-16.85%-15.41% 23.13B
-5.95%-2.58%+29.53%-9.47% 19.36B
-1.14%+0.03%+31.67%-30.65% 17.56B
-5.16%-7.00%+168.44%+314.96% 15.2B
-6.91%-5.83%+25.17%+644.30% 14.83B
+0.43%-1.03%+25.75%+189.74% 14.06B
Average -1.74%-1.97%+30.46%+184.05% 23.36B
Weighted average by Cap. -2.80%-2.35%+39.53%+143.13%

Financials

2026 *2027 *
Net sales - -
Net income -26.61M -23.26M -21.46M -19.78M -37.28M -2.56B -38.11M -257M -101M -1.26B -99.94M -97.75M -4.32B -27.18M -23.75M -21.92M -20.2M -38.08M -2.62B -38.92M -262M -103M -1.28B -102M -99.83M -4.41B
Net Debt - -
Logo Serina Therapeutics, Inc.
Serina Therapeutics Inc. is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. The Company's POZ Platform provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Its proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Its POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. SER-252 is the Company’s lead candidate for advanced Parkinson’s disease. SER-252 is an investigational apomorphine therapy developed with its POZ platform and designed to provide continuous dopaminergic stimulation.
Employees
16
Date Price Change Volume
17/07/26 US$2.130 +7.58% 29,240
16/07/26 US$1.980 +1.54% 31,261
15/07/26 US$1.950 -6.70% 74,236
14/07/26 US$2.090 +1.95% 29,494
13/07/26 US$2.050 -4.21% 37,680
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.130USD
Average target price
9.500USD
Spread / Average Target
+346.01%

Quarterly revenue - Rate of surprise